Niagen Bioscience, Inc. (NASDAQ:NAGE – Get Free Report) has earned an average recommendation of “Buy” from the five ratings firms that are currently covering the firm, MarketBeat.com reports. Five analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $13.42.
NAGE has been the subject of a number of recent research reports. HC Wainwright increased their price objective on shares of Niagen Bioscience from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Monday, August 11th. Wall Street Zen cut shares of Niagen Bioscience from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, September 9th. Canaccord Genuity Group increased their target price on shares of Niagen Bioscience from $13.00 to $16.00 and gave the stock a “buy” rating in a research report on Tuesday, June 10th. Finally, Roth Capital reiterated a “buy” rating and set a $23.00 target price (up previously from $10.00) on shares of Niagen Bioscience in a research report on Friday, June 6th.
View Our Latest Stock Analysis on NAGE
Niagen Bioscience Stock Performance
Niagen Bioscience (NASDAQ:NAGE – Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.02. Niagen Bioscience had a net margin of 15.24% and a return on equity of 23.12%. The company had revenue of $31.12 million during the quarter, compared to analysts’ expectations of $28.55 million.
Institutional Investors Weigh In On Niagen Bioscience
Hedge funds have recently made changes to their positions in the company. State of Wyoming acquired a new stake in shares of Niagen Bioscience during the 4th quarter worth about $39,000. ProShare Advisors LLC acquired a new stake in shares of Niagen Bioscience during the 4th quarter worth about $74,000. Deutsche Bank AG increased its position in shares of Niagen Bioscience by 1,733.4% during the 4th quarter. Deutsche Bank AG now owns 26,878 shares of the company’s stock worth $143,000 after purchasing an additional 25,412 shares in the last quarter. Bank of America Corp DE increased its position in shares of Niagen Bioscience by 89.5% during the 4th quarter. Bank of America Corp DE now owns 52,144 shares of the company’s stock worth $277,000 after purchasing an additional 24,622 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in shares of Niagen Bioscience during the 4th quarter worth about $555,000. Institutional investors and hedge funds own 15.41% of the company’s stock.
Niagen Bioscience Company Profile
Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.
Recommended Stories
- Five stocks we like better than Niagen Bioscience
- Are Penny Stocks a Good Fit for Your Portfolio?
- Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- Cathie Wood Buys Alibaba and Baidu: Momentum or More Value Ahead?
- What Investors Need to Know About Upcoming IPOs
- This ETF Weeds Out Small-Cap Underperformers
Receive News & Ratings for Niagen Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Niagen Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.